Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DALN
2176
DELISTED
DallasNews
DALN
| $2.74M | ﹤0.01% |
242,739
+20,900
| +9% | +$276K |
|
2177
Vulcan Materials
VMC
$36.5B
| $2.73M | ﹤0.01% |
+18,965
| New | +$2.71M |
|
|
LTS
2178
DELISTED
Ladenburg Thalmann Financial Services Inc
LTS
| $2.73M | ﹤0.01% |
784,695
+477,000
| +155% | +$1.38M |
|
2179
Great Elm Group
GEG
$67.7M
| $2.72M | ﹤0.01% |
813,925
-7,779
| -0.9% | -$25.8K |
|
2180
Frequency Electronics
FEIM
$863M
| $2.71M | ﹤0.01% |
265,733
+500
| +0.2% | +$5.36K |
|
2181
American Express
AXP
$231B
| $2.7M | ﹤0.01% |
21,700
-1,938,800
| -99% | -$232M |
|
|
NE
2182
DELISTED
Noble Corporation
NE
| $2.7M | ﹤0.01% |
2,213,437
+1,115,800
| +102% | +$1.34M |
|
2183
Healthcare Realty
HR
$6.6B
| $2.69M | ﹤0.01% |
88,672
-18,528
| -17% | -$554K |
|
|
ROCC
2184
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $2.66M | ﹤0.01% |
87,600
-8,000
| -8% | -$213K |
|
|
MSON
2185
DELISTED
Misonix Inc
MSON
| $2.65M | ﹤0.01% |
142,632
-56,068
| -28% | -$1.03M |
|
2186
Larimar Therapeutics
LRMR
$453M
| $2.65M | ﹤0.01% |
198,806
+16,254
| +9% | +$155K |
|
|
SBT
2187
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $2.65M | ﹤0.01% |
326,833
+105,928
| +48% | +$984K |
|
|
FBMS
2188
DELISTED
The First Bancshares, Inc.
FBMS
| $2.65M | ﹤0.01% |
74,500
+26,000
| +54% | +$863K |
|
|
ERUS
2189
DELISTED
iShares MSCI Russia ETF
ERUS
| $2.65M | ﹤0.01% |
62,000
+8,900
| +17% | +$369K |
|
2190
Crown Crafts
CRWS
$30.7M
| $2.63M | ﹤0.01% |
428,301
+108,301
| +34% | +$711K |
|
2191
Curis
CRIS
$3.76M
| $2.62M | ﹤0.01% |
3,846
+412
| +12% | +$299K |
|
2192
Myriad Genetics
MYGN
$290M
| $2.61M | ﹤0.01% |
+95,900
| New | +$2.64M |
|
2193
Vermilion Energy
VET
$1.73B
| $2.6M | ﹤0.01% |
159,160
-22,882
| -13% | -$345K |
|
2194
Healthcare Services Group
HCSG
$1.48B
| $2.6M | ﹤0.01% |
+106,964
| New | +$2.65M |
|
|
FINV
2195
FinVolution Group
FINV
$1.03B
| $2.6M | ﹤0.01% |
980,300
+318,500
| +48% | +$844K |
|
2196
Grupo SIMEC
SIM
$4.68B
| $2.59M | ﹤0.01% |
254,800
+800
| +0.3% | +$7.57K |
|
2197
Genco Shipping & Trading
GNK
$1.15B
| $2.58M | ﹤0.01% |
243,330
+82,600
| +51% | +$851K |
|
2198
Mueller Industries
MLI
$14.6B
| $2.58M | ﹤0.01% |
+325,200
| New | +$2.49M |
|
|
EGLE
2199
DELISTED
Eagle Bulk Shipping Inc.
EGLE
| $2.55M | ﹤0.01% |
79,078
-64,235
| -45% | -$1.98M |
|
|
NBSE
2200
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $2.54M | ﹤0.01% |
17,660
+4,784
| +37% | +$561K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.